

# GSK Pharma launches two new vaccines

## Our Bureau

Mumbai, Feb. 1

GlaxoSmithKline Pharmaceuticals Ltd (GSK) has brought into the country Boostrix and Infanrix, two of its new innovative vaccines indicated for Diphtheria, Tetanus and acellular Pertussis (DTP).

Unlike traditional vaccines, acellular vaccines provide more comfort to children due to reduced pain, fever and swelling, a GSK note said.

Both products are priced at Rs 699 and will be imported from the GSK Biologicals plant in Belgium, a source fa-

miliar with the development told *Business Line*. Acellular DTP vaccines are part of routine immunisation in over 100 developed and developing countries, the company added.

Infanrix is indicated for childhood immunisation against DTP for newborns from the sixth week. And when combined with Hepatitis B vaccines it reduces the number of pricks and visits to the doctor, the note said.

Boostrix is administered to children above seven years, adolescents and adults and helps boost the waning immunity against DTP.